Literature DB >> 21820207

Hospital antibiotic consumption in Switzerland: comparison of a multicultural country with Europe.

C Plüss-Suard1, A Pannatier, A Kronenberg, K Mühlemann, G Zanetti.   

Abstract

The consumption of antibiotics in the inpatient setting of Switzerland was assessed to determine possible differences between linguistic regions, and to compare these results with European results. Data on antibiotic consumption were obtained from a sentinel network representing 54% of the national acute care hospitals, and from a private drug market monitoring company. Aggregated data were converted into defined daily doses (DDD). The total consumption density in Switzerland was close to the median consumption reported in European surveys. Between 2004 and 2008, the total consumption of systemic antibiotics rose from 46.1 to 54.0 DDD per 100 occupied bed-days in the entire hospitals, and from 101.6 to 114.3 DDD per 100 occupied bed-days in the intensive care units. Regional differences were observed for total consumption and among antibiotic classes. Hospitals in the Italian-speaking region showed a significantly higher consumption density, followed by the French- and German-speaking regions. Hospitals in the Italian-speaking region also had a higher consumption of fluoroquinolones, in line with the reported differences between Italy, Germany and France. Antibiotic consumption in acute care hospitals in Switzerland is close to the European median with a relatively low consumption in intensive care units. Some of the patterns of variation in consumption levels noticed among European countries are also observed among the cultural regions of Switzerland.
Copyright © 2011 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21820207     DOI: 10.1016/j.jhin.2011.05.028

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  13 in total

1.  Regional differences in symptomatic fever management among paediatricians in Switzerland: the results of a cross-sectional Web-based survey.

Authors:  Sebastiano A G Lava; Giacomo D Simonetti; Alessandra Ferrarini; Gian Paolo Ramelli; Mario G Bianchetti
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

Review 2.  Emergence of antibiotic-resistant extremophiles (AREs).

Authors:  Prashant Gabani; Dhan Prakash; Om V Singh
Journal:  Extremophiles       Date:  2012-08-21       Impact factor: 2.395

3.  In Vivo Evolution of CMY-2 to CMY-33 β-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime.

Authors:  João Pires; Magdalena Taracila; Christopher R Bethel; Yohei Doi; Sara Kasraian; Regula Tinguely; Parham Sendi; Robert A Bonomo; Andrea Endimiani
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

4.  Surveillance of Antibiotic Use and Resistance in Intensive Care Units (SARI).

Authors:  Cornelius Remschmidt; Sandra Schneider; Elisabeth Meyer; Barbara Schroeren-Boersch; Petra Gastmeier; Frank Schwab
Journal:  Dtsch Arztebl Int       Date:  2017-12-15       Impact factor: 5.594

5.  Changes in the use of broad-spectrum antibiotics after cefepime shortage: a time series analysis.

Authors:  C Plüss-Suard; A Pannatier; C Ruffieux; A Kronenberg; K Mühlemann; G Zanetti
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

Review 6.  A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa.

Authors:  Anne F Voor In 't Holt; Juliëtte A Severin; Emmanuel M E H Lesaffre; Margreet C Vos
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

7.  Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy?

Authors:  Markus Hilty; Parham Sendi; Salome N Seiffert; Sara Droz; Vincent Perreten; Andrea M Hujer; Robert A Bonomo; Kathrin Mühlemann; Andrea Endimiani
Journal:  Int J Antimicrob Agents       Date:  2013-01-10       Impact factor: 5.283

8.  Comparison of Chiropractic Treatment Outcomes Depending on the Language Region in Switzerland: A Prospective Outcomes Study.

Authors:  David A Guillén; Cynthia K Peterson; B Kim Humphreys
Journal:  J Chiropr Humanit       Date:  2017-06-17

9.  No evidence so far for the dissemination of carbapenemase-producing Enterobactericeae in the community in Switzerland.

Authors:  Magdalena Nüesch-Inderbinen; Katrin Zurfluh; Herbert Hächler; Roger Stephan
Journal:  Antimicrob Resist Infect Control       Date:  2013-09-04       Impact factor: 4.887

10.  Causes, coping, and culture: a comparative survey study on representation of back pain in three Swiss language regions.

Authors:  Peter J Schulz; Uwe Hartung; Silvia Riva
Journal:  PLoS One       Date:  2013-11-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.